Proprietary AI analyst is now available

Pacific Edge Valuation Multiples

Discover revenue and EBITDA valuation multiples for Pacific Edge and similar public comparables like Quantum-Si, Genomictree, Korro Bio, Insight Molecular and more.

Pacific Edge Overview

About Pacific Edge

Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World.


Founded

2001

HQ

New Zealand

Employees

122

Financials (LTM)

Revenue: $8M
EBITDA: ($20M)

EV

$205M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Pacific Edge Financials

Pacific Edge reported last 12-month revenue of $8M and negative EBITDA of ($20M).

In the same LTM period, Pacific Edge generated $835K in gross profit, ($20M) in EBITDA losses, and had net loss of ($20M).

Revenue (LTM)


Pacific Edge P&L

In the most recent fiscal year, Pacific Edge reported revenue of $13M and EBITDA of ($18M).

Pacific Edge is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (145%), and net margin of (137%).

See analyst estimates for Pacific Edge
LTMLast FY202320242025202620272028
Revenue$8M$13M$13M$13M$8M
Gross Profit$835K$13M$13M$13M$3M
Gross Margin11%100%100%100%41%
EBITDA($20M)($18M)($19M)($19M)($20M)
EBITDA Margin(256%)(145%)(148%)(145%)(242%)
EBIT Margin(269%)(156%)(157%)(156%)(255%)
Net Profit($20M)($17M)($17M)($17M)($20M)
Net Margin(264%)(137%)(127%)(133%)(245%)

Financial data powered by Morningstar, Inc.

Pacific Edge Stock Performance

Pacific Edge has current market cap of $208M, and enterprise value of $205M.

Market Cap Evolution


Pacific Edge's stock price is $0.18.

Pacific Edge share price increased by 6.2% in the last 30 days, and by 216.2% in the last year.

Pacific Edge has an EPS (earnings per share) of $-0.01.

See more trading valuation data for Pacific Edge
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$205M$208M-0.0%6.2%72.9%216.2%$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Pacific Edge Valuation Multiples

Pacific Edge trades at 26.7x EV/Revenue multiple, and (10.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for Pacific Edge

EV / Revenue (LTM)


Pacific Edge Financial Valuation Multiples

As of June 22, 2026, Pacific Edge has market cap of $208M and EV of $205M.

Pacific Edge has a P/E ratio of (10.3x).

LTMLast FY202320242025202620272028
EV/Revenue26.7x16.3x15.6x16.0x25.0x
EV/EBITDA(10.4x)(11.2x)(10.6x)(11.0x)(10.3x)
EV/EBIT(9.9x)(10.5x)(9.9x)(10.3x)(9.8x)
EV/Gross Profit245.1x16.3x15.6x16.0x61.1x
P/E(10.3x)(12.1x)(12.6x)(12.2x)(10.4x)
EV/FCF(8.8x)(13.7x)(13.0x)(13.6x)(9.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Pacific Edge Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Pacific Edge Margins & Growth Rates

Pacific Edge decreased revenue by 46% but EBITDA grew by 12% in the last fiscal year.

In the most recent fiscal year, Pacific Edge reported gross margin of 100%, EBITDA margin of (145%), and net margin of (137%).

See estimated margins and future growth rates for Pacific Edge

Pacific Edge Margins

Last FY202420252026202720282029
Gross Margin100%100%41%21%
EBITDA Margin(145%)(145%)(242%)(183%)
EBIT Margin(156%)(156%)(255%)(194%)
Net Margin(137%)(133%)(245%)(190%)
FCF Margin(119%)(118%)(260%)(233%)

Pacific Edge Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(46%)(2%)(36%)19%
Gross Profit Growth(98%)(2%)(74%)(38%)
EBITDA Growth12%(4%)7%(10%)
EBIT Growth9%(3%)5%(10%)
Net Profit Growth22%3%17%(8%)
FCF Growth57%(4%)42%6%

Data powered by FactSet, Inc. and Morningstar, Inc.

Pacific Edge Operational KPIs

Pacific Edge's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.

Pacific Edge's Rule of 40 is (164%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pacific Edge's Rule of X is (136%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Pacific Edge
LTMLast FY202320242025202620272028
Rule of 40(185%)(164%)---
Bessemer Rule of X(79%)(136%)---
Revenue per Employee-$0.1M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue120%80%112%87%112%
G&A Expenses to Revenue69%27%50%32%59%
R&D Expenses to Revenue103%67%22%55%98%
Opex to Revenue-256%257%256%391%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Pacific Edge Competitors

Pacific Edge competitors include Quantum-Si, Genomictree, Korro Bio, Insight Molecular, Diaceutics, Vitrafy, Alpha Teknova, Curiosis, Nautilus Biotechnology and Bioventix.

Most Pacific Edge public comparables operate across Life Sciences Tools.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Quantum-Si38.6x53.0x(1.2x)(1.1x)
Genomictree58.5x-(28.5x)-
Korro Bio18.2x27.9x(1.4x)(1.2x)
Insight Molecular37.1x47.8x(5.7x)(5.6x)
Diaceutics3.1x2.8x19.3x-
Vitrafy2920.3x645.1x(15.0x)(10.8x)
Alpha Teknova7.2x6.9x(43.4x)(39.7x)
Curiosis23.6x15.4x(26.4x)(48.5x)

This data is available for Pro users. Sign up to see all Pacific Edge competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Pacific Edge

When was Pacific Edge founded?Pacific Edge was founded in 2001.
Where is Pacific Edge headquartered?Pacific Edge is headquartered in New Zealand.
How many employees does Pacific Edge have?As of today, Pacific Edge has over 122 employees.
Is Pacific Edge publicly listed?Yes, Pacific Edge is a public company listed on New Zealand Exchange.
What is the stock symbol of Pacific Edge?Pacific Edge trades under PEB ticker.
When did Pacific Edge go public?Pacific Edge went public in 2003.
Who are competitors of Pacific Edge?Pacific Edge main competitors include Quantum-Si, Genomictree, Korro Bio, Insight Molecular, Diaceutics, Vitrafy, Alpha Teknova, Curiosis, Nautilus Biotechnology, Bioventix.
What is the current market cap of Pacific Edge?Pacific Edge's current market cap is $208M.
What is the current revenue of Pacific Edge?Pacific Edge's last 12 months revenue is $8M.
What is the current revenue growth of Pacific Edge?Pacific Edge revenue growth (NTM/LTM) is 71%.
What is the current EV/Revenue multiple of Pacific Edge?Current revenue multiple of Pacific Edge is 26.7x.
Is Pacific Edge profitable?No, Pacific Edge is not profitable.
What is the current EBITDA of Pacific Edge?Pacific Edge has negative EBITDA and is not profitable.
What is Pacific Edge's EBITDA margin?Pacific Edge's last 12 months EBITDA margin is (256%).
What is the current EV/EBITDA multiple of Pacific Edge?Current EBITDA multiple of Pacific Edge is (10.4x).
What is the current FCF of Pacific Edge?Pacific Edge's last 12 months FCF is ($23M).
What is Pacific Edge's FCF margin?Pacific Edge's last 12 months FCF margin is (304%).
What is the current EV/FCF multiple of Pacific Edge?Current FCF multiple of Pacific Edge is (8.8x).
How many companies Pacific Edge has acquired to date?Pacific Edge hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Pacific Edge has invested to date?Pacific Edge hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Pacific Edge

Lists including Pacific Edge

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial